{"id":"fluzoparib-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PARP inhibitors like fluzoparib trap PARP proteins on damaged DNA, preventing single-strand break repair and leading to double-strand breaks and apoptosis. This mechanism is particularly effective in tumors with BRCA mutations or homologous recombination deficiency, where alternative DNA repair pathways are compromised. Fluzoparib is being evaluated as monotherapy in various cancer types.","oneSentence":"Fluzoparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and inducing cell death in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:11.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"BRCA-mutated ovarian cancer"},{"name":"BRCA-mutated breast cancer"},{"name":"Homologous recombination deficient tumors"}]},"trialDetails":[{"nctId":"NCT07321015","phase":"PHASE2","title":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-20","conditions":"Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not","enrollment":72},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06954584","phase":"PHASE3","title":"Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-05-27","conditions":"Ovarian Cancer","enrollment":424},{"nctId":"NCT04517357","phase":"PHASE2","title":"A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-10-16","conditions":"Relapsed Ovarian Cancer","enrollment":100},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT06735326","phase":"PHASE2","title":"Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-11-27","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":105},{"nctId":"NCT06541314","phase":"PHASE2","title":"Fluzoparib Neoadjuvant Therapy for Ovarian Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-06-18","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT04228601","phase":"PHASE1, PHASE2","title":"A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-01-21","conditions":"Advanced Pancreatic Cancer","enrollment":39},{"nctId":"NCT04300114","phase":"PHASE3","title":"A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-08-19","conditions":"Metastatic Pancreatic Cancer","enrollment":5},{"nctId":"NCT06055166","phase":"PHASE2","title":"A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-11-01","conditions":"PARP Inhibitor for Esophageal Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT05479487","phase":"PHASE2","title":"Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment","status":"NOT_YET_RECRUITING","sponsor":"Xiaohua Wu MD","startDate":"2022-08-01","conditions":"Relapsed Ovarian Cancer","enrollment":132},{"nctId":"NCT05206890","phase":"","title":"A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-14","conditions":"Ovarian Cancer","enrollment":490},{"nctId":"NCT05170594","phase":"PHASE2","title":"A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Shandong First Medical University","startDate":"2021-12-24","conditions":"Ovarian Cancer","enrollment":60},{"nctId":"NCT04425876","phase":"PHASE1","title":"A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-12-17","conditions":"Pancreatic Cancer","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluzoparib Monotherapy","genericName":"Fluzoparib Monotherapy","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluzoparib is a small molecule PARP inhibitor used in various clinical trials for conditions such as platinum-sensitive advanced triple-negative breast cancer, ovarian cancer, and esophageal squamous cell carcinoma. It has been studied as a monotherapy in a single-arm phase II study for platinum-sensitive advanced triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}